Cidara Therapeutics (CDTX) to Release Quarterly Earnings on Thursday

Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($1.87) per share for the quarter.

Cidara Therapeutics (NASDAQ:CDTX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($5.45) by $3.79. On average, analysts expect Cidara Therapeutics to post $-9 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Cidara Therapeutics Stock Performance

Shares of CDTX stock traded down $0.41 during trading hours on Friday, reaching $62.90. The company had a trading volume of 302,038 shares, compared to its average volume of 646,574. Cidara Therapeutics has a twelve month low of $10.14 and a twelve month high of $66.94. The company has a market capitalization of $1.27 billion, a P/E ratio of -2.13 and a beta of 1.18. The stock's fifty day simple moving average is $41.88 and its 200 day simple moving average is $28.39.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CDTX shares. HC Wainwright restated a "buy" rating and set a $53.00 price objective (up previously from $41.00) on shares of Cidara Therapeutics in a research note on Monday, June 23rd. JMP Securities restated a "market outperform" rating and set a $59.00 price objective on shares of Cidara Therapeutics in a research note on Monday, June 30th. Guggenheim set a $69.00 price objective on Cidara Therapeutics in a research note on Wednesday, July 9th. Wall Street Zen upgraded Cidara Therapeutics to a "sell" rating in a research report on Saturday, May 10th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Cidara Therapeutics in a research report on Tuesday, June 10th. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $57.29.

Insider Activity

In related news, Director Ra Capital Management, L.P. purchased 2,272,727 shares of the business's stock in a transaction that occurred on Thursday, June 26th. The shares were acquired at an average price of $44.00 per share, with a total value of $99,999,988.00. Following the acquisition, the director owned 3,365,523 shares in the company, valued at approximately $148,083,012. This trade represents a 207.97% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.89% of the company's stock.

Institutional Trading of Cidara Therapeutics

An institutional investor recently raised its position in Cidara Therapeutics stock. Jane Street Group LLC raised its holdings in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX - Free Report) by 119.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,849 shares of the biotechnology company's stock after acquiring an additional 15,135 shares during the period. Jane Street Group LLC owned approximately 0.22% of Cidara Therapeutics worth $600,000 as of its most recent SEC filing. Institutional investors own 35.82% of the company's stock.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.